Patent Number: 6,169,079

Title: Oligonucleotide inhibition of cell adhesion

Abstract: Compositions and methods are provided for the treatment and diagnosis of diseases amenable to treatment through modulation of the synthesis or metabolism of intercellular adhesion molecules. In accordance with preferred embodiments, oligonucleotides are provided which are specifically hybridizable with nucleic acids encoding intercellular adhesion molecule-1, vascular cell adhesion molecule-1, and endothelial leukocyte adhesion molecule-1. The oligonucleotide comprises nucleotide units sufficient in identity and number to effect said specific hybridization. In other preferred embodiments, the oligonucleotides are specifically hybridizable with a transcription initiation site, a translation initiation site, 5'-untranslated sequences, 3'-untranslated sequences, and intervening sequences. Methods of treating animals suffering from disease amenable to therapeutic intervention by modulating cell adhesion proteins with an oligonucleotide specifically hybridizable with RNA or DNA corresponding to one of the foregoing proteins are disclosed. Methods for treatment of diseases responding to inhibition of cell adhesion molecules are disclosed.

Inventors: Bennett; C. Frank (Carlsbad, CA), Mirabelli; Christopher K. (Dover, MA)

Assignee: Isis Pharmaceuticals Inc.

International Classification: A01N 43/02 (20060101); A01N 43/04 (20060101); A61K 31/70 (20060101); A61K 48/00 (20060101); C07H 21/02 (20060101); C07H 21/00 (20060101); C07H 21/04 (20060101); C12P 19/00 (20060101); C12Q 1/68 (20060101); C12P 19/34 (20060101); A01N 043/04 (); A61K 031/70 (); C07H 021/04 (); C12Q 001/68 (); C12P 019/34 ()

Expiration Date: 01/02/2018